Integrated Solutions. Proven Performance. Reliable Results.
Customer Perspectives
During my internship, I had a very good impression of Leica instruments, Leica microscopes, and Leica optics. Whenever we had problems, Leica promptly came to help us. So, when I opened my private lab, I had no doubts it had to be Leica. I’ve always felt Leica wanted to help us and to be a partnership.
Translated from source language.
Isabel Macedo Pinto
Pathologist and Founder of IMP Diagnostics
“The Leica Biosystems team understand that standardisation and interoperability are vital for the adoption of digital pathology and development of artificial intelligence. We value their methodical and practical approach, helping pathology to become increasingly digital and advancing our work at the UK National Pathology Imaging Co-operative program.”
Translated from source language.
Dr. Darren Treanor, MB, BSc (Computing), PhD, FRCPath
Director, National Pathology Imaging Co-operative, UK
Consultant Histopathologist, Leeds Teaching Hospitals NHS Trust, UK
Honorary Clinical Professor, University of Leeds, UK
Adjunct Professor in Digital Pathology, Linköping University, Sweden
News & Promotions
Aperio GT 450 Scanner – Leading Innovation with Proven Technology
With over 25 years of Digital Pathology innovation, Leica Biosystems delivers performance and reliability.
The Aperio GT 450 scanner offers state-of-the-art enhancements, including Manual Scan capabilities, DICOM compatible files, Extended Focus for composite in-focus images, and Aperio iQC Software.
For research use only. Not for use in diagnostic procedures.
Leica Biosystems Newcastle Center for Enabling Precision Medicine Achieves CLIA Certification
Leica Biosystems has received a Clinical Laboratory Improvement Amendments (CLIA) certification for its state-of-the-art research and development facility in Newcastle, United Kingdom.
Leica Biosystems and Indica Labs Announce Significant Strategic Investment and Creation of Digital Pathology Platform
Combining leading hardware and software is expected to provide a compelling solution for digital pathology users across the full translational medicine paradigm, from early biomarker discovery to clinical trials, and through to routine diagnostics.